A family of structurally related proteins homologous to the Drosophila mothers against dpp (MAD) gene product have been implicated in signal transduction by members of the TGF-b superfamily. One of these MAD related proteins (DPC4) has been cloned as a candidate tumour suppressor in pancreas carcinomas, suggesting a role for DPC4 in growth regulation by TGF-b related proteins. The involvement of DPC4 in TGF-b1 induced growth inhibition and transcriptional response is demonstrated here, by the introduction of DPC4 in the TGF-b and activin insensitive breast tumour cell line MDA-MB-468, from which the DPC4 gene is deleted. Transfection of DPC4 in this cell line restores both growth inhibition and the induction of a TGF-b sensitive reporter construct (3TPlux) by TGF-b1. In contrast, a DPC4 splice variant lacking amino acid residues 223 ± 301 and cloned from another TGF-b and activin resistant breast tumour cell line (MDA-MB-231), does not restore the induction of the 3TPlux reporter by TGF-b1. We also show that in this latter cell line activin resistance is partly due to the absence of a functional activin type IB receptor. These results indicate that DPC4 is part of the TGF-b signalling cascade and mediates TGF-b induced growth inhibition. Together with the deletion of DPC4 from pancreas carcinomas these results suggest a role for DPC4 as a tumour suppressor.
Introduction
TGF-b is a member of a large superfamily of structurally related growth and dierentiation factors, including activin, inhibin, bone morphogenetic proteins (BMPs), MuÈ llerian inhibiting substance (MIS) and growth and dierentiation factors (GDFs). These factors are important regulators of cell dierentiation and proliferation and exert their eects via speci®c serine/threonine kinase transmembrane receptors (type II receptors). Upon ligand binding the type II receptors combine with and phosphorylate related serine/ threonine kinase receptors (type I receptors). The phosphorylated type I receptors can subsequently convey signals to the inside of the cell resulting in cellular responses like growth inhibition Attisano et al., 1996) .
TGF-b has been reported as a potent inhibitor of normal mammary epithelial cell proliferation both in vitro (Hosebuchi and Stampfer, 1989; Valverius et al., 1989) and in vivo (Silberstein and Daniel, 1987) . However, epithelial derived tumour cells, including those from breast tumours (Ji et al., 1994; Sun et al., 1994; Kalkhoven et al., 1995) , have often lost their sensitivity to TGF-b, due to the absence of the TGF-b type II receptor and mutations in this receptor have been found in several human tumour types (reviewed by Markowitz and Roberts, 1996) . Recently, we demonstrated that the absence of growth inhibition by TGF-b and activin correlates with the absence of receptor protein in a number of human breast tumour cell lines (Kalkhoven et al., 1995) . Interestingly, in two estrogen receptor negative cell lines that are not growth inhibited by TGF-b and activin (MDA-MB-231 and MDA-MB-468) the presence of TGF-b and activin receptor protein was clearly shown (Kalkhoven et al., 1995) . The TGF-b and activin resistance in these cells can be explained by either inactivating mutations in the TGF-b and activin receptors or, more likely, by defects in common components of the signalling pathway downstream of the TGF-b and activin receptors. Potential candidate genes that might be mutated in these breast tumour cell lines are the genes encoding MAD related proteins, which have been implicated in the signal transduction pathway of the TGF-b superfamily members (Riggins et al., 1996;  for review see MassagueÂ , 1996) . A member of this family of MAD related genes (DPC4) has been isolated as a candidate tumour suppressor gene, which is deleted or mutated in pancreatic carcinomas . Inactivating mutations in another member of this gene family (Smad2) have been found in colorectal carcinomas (Eppert et al., 1996; Thiagalingram et al., 1996) . Possibly both genes are involved in the TGF-b signal transduction pathway leading to growth inhibition. Since loss of heterozygosity of chromosome 18q, on which DPC4 and Smad2 are located, is often found in breast tumours (Bieche and Lidereau, 1995) , we reasoned that the absence of growth inhibition in MDA-MB-231 and MDA-MB-468 cells might result from the absence of DPC4 or Smad2. Therefore, the expression of DPC4 and Smad2 in TGF-b and activin sensitive and insensitive breast tumour cell lines was studied. It was found that DPC4 is deleted in MDA-MB-468 cells as has been described recently , whereas Smad2 is expressed in these cells. In MDA-MB-231 both DPC4 and Smad2 are expressed. Transfection of DPC4 in MDA-MB-468 cells restored both growth inhibition and the induction of a TGF-b sensitive reporter construct (3TPlux) by TGF-b1, indicating that DPC4 is involved in TGF-b induced growth inhibition and transcriptional response.
Results
Recently, we described two estrogen receptor negative breast tumour cell lines (MDA-MB-231 and MDA-MB-468), that are insensitive to growth inhibition by TGF-b and activin, despite the presence of TGF-b and activin receptor protein at their cell surface (Kalkhoven et al., 1995) . This observation suggested a defect in a common downstream component(s) of the TGF-b and activin signalling cascade in these cell lines, although inactivating mutations at the receptor level might also be present. Since MAD related proteins play an important role in the signalling pathway of the TGF-b superfamily members, a defect in a gene encoding one of these proteins might be found in the MDA-MB-231 and MDA-MB-468 cell lines. Potential candidate genes in this respect are DPC4 and Smad2, which have been described as tumour suppressor genes in pancreas carcinomas and colorectal carcinomas (Eppert et al., 1996; Thiagalingam et al., 1996) . Furthermore, loss of heterozygosity of chromosome 18q, on which these genes are located is often found in breast tumours (Bieche and Lidereau, 1995) . Therefore, we investigated the expression of these MAD related proteins in the TGF-b and activin resistant (MDA-MB-231 and MDA-MB-468) and sensitive (MCF-7 and T47D) breast tumour cell lines by RT ± PCR and Northern blot analysis. RT ± PCR showed the presence of a DPC4 transcript in MCF-7 breast tumour cells (Figure 1a ). In contrast, the DPC4 transcript was absent in MDA-MB-468 cells ( Figure  1a ), due to a deletion of the DPC4 gene, as demonstrated by Southern blot analysis (not shown) and as has been con®rmed recently . In MDA-MB-231 cells RT ± PCR detected two DPC4 transcripts (Figure 1a) , whereas Southern blot analysis demonstrated the DPC4 gene in MDA-MB-231 cells as well as in MCF-7 and T47D breast tumour cells (not shown). Northern blot analysis on total RNA showed the expression of DPC4 mRNA in MDA-MB-231 and T47D breast tumour cells, but this assay did not reveal a transcript in the MCF-7 and MDA-MB-468 cell line (Figure 1b) . Since RT ± PCR did detect a DPC4 transcript in MCF-7 cells the DPC4 gene is not highly expressed in these cells. The gene encoding Smad2 was detected in all four cell lines by Southern blot analysis (not shown). Northern blot analysis demonstrated the presence of Smad2 mRNA in T47D, MDA-MB-231 and MDA-MB-468 cells, whereas in MCF-7 the Smad2 expression was below the detection limit of the assay (Figure 1b) . These results indicate that the absence of DPC4 might be responsible for the lack of TGF-b and activin eects in MDA-MB-468 cells.
To study the consequences of the DPC4 deletion on other TGF-b and activin induced responses, the induction of the TGF-b and activin responsive reporter constructs 3TPlux (Wrana et al., 1992) and PAIluc (Keeton et al., 1991) was investigated in the MDA-MB-468 cell line. Although in CHO cells TGFb1 and activin-A can induce both reporter constructs, no reporter induction was found in MDA-MB-468 cells (Figure 2a ), suggesting that DPC4 mediates both growth inhibition and transcriptional activation of these reporter constructs. In the MDA-MB-231 cell line, that expresses DPC4 and Smad2 mRNA but is resistant to growth inhibition by TGF-b and activin, only TGF-b is able to induce these reporter constructs (Figure 2a ). Since the activin type IB receptor mediates growth inhibition and the induction of the 3TPlux reporter construct by activin (Carcamo et al., 1994) , (231) and MDA-MB-468 (468) breast tumor cells using oligonucleotides corresponding to bp 28 ± 47 and bp 1767 ± 1786 of the human DPC4 sequence . The upper arrow indicates the expected 1759 bp product, whereas the lower arrow indicates a 1523 bp alternatively spliced DPC4 transcript. Water was used as a negative control. The two DPC4 transcripts in MDA-MB-231 cells were detected in two independent RT ± PCR reactions. (b) Northern blot analysis of DPC4 and Smad2 mRNA in breast tumor cells. Twenty microgram of total RNA from T47D, MDA-MB-231, MDA-MB-468 and MCF-7 breast tumor cells was electrophoresed in a 0.8% denaturing agarose gel and blotted onto a nitrocellulose ®lter. The ®lter was hybridized with 32 Plabelled cDNA probes corresponding to the entire coding sequence of DPC4, Smad2 and GAPDH as a control. (c) Alignment of the proline rich linker region of DPC4 encoded by the two DPC4 transcripts cloned from MDA-MB-231 cells. The amino acid sequence encoded by the 1759 bp (DPC4) and the 1523 bp (DPC4*) transcripts corresponding to amino acid residues 201 to 350 of the human DPC4 sequence is aligned. Underlined amino acid residues denote amino acid dierences compared to the described DPC4 sequence this receptor was transiently transfected in MDA-MB-231 cells, to determine whether the activin insensitivity was located at the level of the activin type I receptor. After cotransfection of the activin type IB receptor with the 3TPlux reporter construct an activin response on this reporter was detected (Figure 2b ). These results indicate that the signalling components necessary for the induction of the 3TPlux and PAIluc reporter constructs by TGF-b and activin (e.g. DPC4) are intact in MDA-MB-231 cells and that these cells lack a functional activin type IB receptor.
To be able to study the role of DPC4 in MDA-MB-468 cells, the two DPC4 transcripts were cloned from MDA-MB-231 cells and subjected to sequence analysis. The longest transcript (1759 bp) encodes the described DPC4 protein (with a mutation of proline 303 to leucine (P303L)), whereas the smaller transcript is an alternatively spliced DPC4 mRNA, missing exon 5 and 6 (nucleotides 797 to 1033) of the DPC4 gene. The latter transcript encodes a DPC4 protein lacking amino acid residues 223 to 301 in the proline rich linker region between the conserved domains MH1 and MH2 ( Figure 1c ), with additional H92R and Q334R mutations. Transient transfection of the`wild type' DPC4 cDNA construct in the DPC4 negative MDA-MB-468 cells restored the induction of the 3TPlux reporter construct by TGF-b1, but did not result in a clear activin response (Figure 3 ). Unlike the`wild type' DPC4 protein, the shorter DPC4 product or Smad2 did not restore the 3TPlux induction by TGF-b or activin ( Figure 3 ). Smad2 did also not enhance the eect of`wild type' DPC4 ( Figure 3 ), whereas the shorter DPC4 product did not inhibit the TGF-b induced 3TPlux induction in MDA-MB-468 cells transiently transfected with DPC4 or in mink lung cells (not shown). The lack of 3TPlux induction by activin was not rescued by transient transfection of activin type I (IB) and II (IIA or IIB2) receptors together with DPC4 or Smad2 (not shown), pointing to a possible defect in the activin speci®c part of the signalling pathway in MDA-MB-468 cells.
The role of DPC4 in TGF-b induced growth inhibition was studied in MDA-MB-468 cells stably transfected with the DPC4 cDNA construct. Stable transfection of MDA-MB-468 cells yielded several G418 resistant clones, which were ®rst tested for growth inhibition by TGF-b1. In two cell lines (clones 9 and 13) growth inhibition by TGF-b was restored to levels comparable to the TGF-b and activin sensitive MCF-7 cell line ( Figure 4 ). Restoration of TGF-b1 induced growth inhibition in clone 13 was found in three independent experiments. Remarkably, the basal growth rate of clone 9 was strongly reduced compared to the other cell lines when cells were cultured for a long time and the TGF-b response disappeared (not shown). Like the induction of the 3TPlux construct the activin response in this growth inhibition assay was not restored (not shown). Northern blot analysis demonstrated that the TGF-b , 1996) sensitive clones 9 and 13 express the DPC4 mRNA, whereas the TGF-b insensitive cell lines do not ( Figure  5a ). The DPC4 transcript detected in clone 13 encodes the entire DPC4 protein, since RT ± PCR with primers in the 5' and 3' untranslated region of the DPC4 gene detected a product of the expected size (Figure 5b ). The smaller transcript in clone 9 probably encodes a N-terminally truncated DPC4 protein since RT ± PCR only detected a product with primer 418 located 289 bp 3' from the translation initiation site (Figure 5b ). RT ± PCR did not detect a DPC4 transcript in the TGF-b insensitive clones 11 and 12. The translation of the DPC4 transcript in clone 13 was demonstrated by the detection of the DPC4 protein by Western blotting with a DPC4 speci®c antibody (Figure 5c ). The antibody against amino acid residues 184 ± 203 in the nonconserved region of the proline rich linker region of the DPC4 protein did not detect a protein in clone 9 and clone 11, indicating that the antibody epitope is not present in the DPC4 protein encoded by the small DPC4 transcript in clone 9.
All together, these results show the involvement of DPC4 in growth inhibition and transcriptional response by TGF-b. Together with its deletion in pancreas carcinomas these results suggest that DPC4 has the properties of a tumour suppressor gene.
Discussion
In normal tissue, a proper control of cellular proliferation prevents unbridled cell growth. During the last decades numerous factors involved in this control process have been identi®ed. Among these factors several tumour suppressors have been described, which normally participate in the inhibition of cellular proliferation. Mutations that inactivate these tumour suppressors can lead to uncontrolled cell growth and thus might contribute to the progression towards malignancy. Recently, two members of the family of MAD related proteins (DPC4 and Smad2) have been isolated as candidate tumour suppressors in pancreatic carcinomas and colorectal carcinomas, respectively Eppert et al., 1996; Thiagalingam et al., 1996) . In the present study we demonstrate that DPC4 mediates growth inhibition by TGF-b1 in breast tumour cells and suggest that DPC4 has the potency of a tumour suppressor gene.
Mothers against dpp (MAD) has been identi®ed as a downstream component of the signalling cascade of the TGF-b related decapentaplegic (dpp) protein by a genetic screen in Drosophila (Sekelsky et al., 1995) . The MAD gene turned out to be homologous to the Sma genes from Caenorhabditis elegans, which mediate restores 3TPlux induction by TGF-b1 in MDA-MB-468 breast tumour cells. MDA-MB-468 cells were transiently transfected with 3 mg 3TPlux reporter construct and 3 mg lac-Z reporter construct alone (control) or in combination with 1 mg cDNA encoding DPC4 (dpc4), alternatively spliced DPC4 (dpc4*), Smad2 (smad2) or DPC4 and Smad2 (dpc4 smad2). Cells were treated for 16 h with TGF-b1 (10 ng/ml) or activin-A (50 ng/ml). Induction of luciferase activity was determined as indicated in Figure 2a signal transduction by the TGF-b receptor like serine/ threonine kinase daf-4 . Several mammalian homologs of MAD have just been identi®ed and have been implicated in the signal transduction pathway of the TGF-b superfamily members Chen et al., 1996; Eppert et al., 1996; Gra et al., 1996; Hoodless et al., 1996; Lagna et al., 1996; Liu et al., 1996; Riggins et al., 1996; Yingling et al., 1996; Zhang et al., 1996) . The MAD related proteins are characterized by conserved amino-and carboxy-terminal domains separated by a proline rich linker region of variable sequence and length. Nevertheless, their function cannot be deduced from their protein sequence, since no functional motifs are present.
The MAD related protein Smad1 has been implicated in the BMP signalling pathway leading to the formation of ventral mesoderm in Xenopus embryos (Gra et al., 1996; Liu et al., 1996) . Upon activation of BMP type I receptors Smad1 is phosphorylated and translocated from the cytoplasm to the nucleus . In the nucleus Smad1 may play a role in transcription activation, since the conserved carboxy-terminal part of Smad1 possesses transcriptional activity when fused to a DNA-binding domain (Liu et al., 1996) . In contrast to Smad1, Smad2 seems to be involved in the signal transduction pathway of activin, as it mimics the formation of dorsal mesoderm in Xenopus embryos by activin Gra et al., 1996) and cooperates with a winged-helix transcription factor (FAST1) to stimulate the transcription of the Mix-2 gene (Chen et al., 1996) . Smad2 is also involved in the TGF-b signal transduction pathway, because it is phosphorylated in response to TGF-b (Eppert et al., 1996) and cooperates with DPC4 to transduce both the TGF-b and activin signals (Lagna et al., 1996) . Another MAD related protein (Smad3) is also phosphorylated upon activation of the TGF-b receptor complex and induces ligand independent transcription of a PAI promoter reporter construct . The eect of Smad3 is strongly potentiated by DPC4 , indicating that these MAD related proteins may form an active heteromeric complex that functions as a transcriptional regulator. The involvement of DPC4 in the TGF-b signalling pathways via Smad2 and Smad3 suggests that the absence of DPC4 might cause insensitivity to TGF-b.
In this paper we propose that the absence of DPC4 in MDA-MB-468 breast tumour cells might be responsible for the lack of TGF-b responses in these cells. Transfection of DPC4 restored both TGF-b induced growth inhibition and transcriptional response, indicating that DPC4 is part of the TGF-b signal transduction pathway leading to growth inhibition and plasminogen activator inhibitor 1 (PAI-1) induction. Although the eects of DPC4 transfection P-labelled cDNA probes corresponding to the entire coding sequence of DPC4 and GAPDH as a control. The position of the 18S ribosomal RNA band is indicated on the right. The upper arrow indicates the normal DPC4 transcript, the lower arrow indicates the smaller transcript in clone 9. (b) RT ± PCR ampli®cation of DPC4 mRNA from stably transfected MDA-MB-468 breast tumour cells. cDNA from clones 9, 11, 12 and 13 was obtained by reverse transcription of total RNA using an oligonucleotide corresponding to bp 1767 ± 1786 of the human DPC4 sequence . PCR was performed with oligonucleotides corresponding to bp 28 ± 47 (28) or bp 418 ± 437 (418) of the human DPC4 sequence as forward primer and an oligonucleotide corresponding to bp 1329 ± 1348 (1348) of the human DPC4 sequence as reverse primer. As a positive control pcDNA3 containing the entire DPC4 cDNA was used, water was used as a negative control. (c) Western blot of DPC4 protein in stably transfected MDA-MB-468 cells. Protein samples from clones 9, 11 and 13 were separated by SDS ± PAGE and electrotransferred to Immobilon-P. DPC4 protein was detected using a polyclonal antibody against amino acid region 184 ± 203 in the nonconserved proline rich linker region of the DPC4 protein, which was visualized with streptavidin-horseradish peroxidase conjugate using the enhanced chemoluminescence system. The arrow indicates the DPC4 protein are moderate they are reproducable, since similar eects have been found in independent experiments. Moreover, in a study which was published during the preparation of our manuscript (Lagna et al., 1996) , DPC4 restored the ability of TGF-b to induce the 3TPlux reporter construct in MDA-MB-468 cells to similar levels as found in our study. The induction of the 3TPlux reporter construct by TGF-b in MDA-MB-468 breast tumour cells transfected with DPC4 is comparable to the induction found in MDA-MB-231 breast tumour levels, but much lower than in CHO cells. This indicates that the level of induction of the 3TPlux reporter construct is cell type dependent and in general low in breast tumour cells. Strikingly in this respect is the fact that TGF-b can induce PAIluc and 3TPlux reporters to similar levels in MDA-MB-231 cells, whereas in CHO cells the 3TPlux reporter is induced to higher levels than the PAIluc reporter. This points to dierences in the TGF-b signalling pathway in these cells, that probably involves the three TPA responsive elements that are present in the 3TPlux reporter. In MDA-MB-231 and MDA-MB-468 cells increased binding activity of AP1 transcription factor complexes, which can bind to TPA responsive elements, has been found ( Van der Burg et al., 1995) . Possibly, the moderate eects of TGF-b in these breast tumour cells are due to the constitutive activation of AP1 transcription factor complexes, which prevents the activation of the TPA responsive elements in the 3TPlux reporter constructs by TGF-b and might correlate with the hormone independent growth of these breast tumour cells. However, we cannot exclude additional defects in the TGF-b signalling pathway that might be involved in the TGF-b resistance of MDA-MB-468 cells.
Although in one of the stably transfected MDA-MB-468 cell lines (clone 13) the restoration of growth inhibition by TGF-b clearly correlates with the presence of a DPC4 mRNA transcript and DPC4 protein, this correlation was less clear in the TGF-b sensitive clone 9. In this clone a smaller DPC4 mRNA transcript was detected, which possibly encodes an Nterminally truncated DPC4 protein that is not recognized by antiserum against amino acid residues 184 ± 203 in the proline rich linker region of the DPC4 protein. It should be noted here that we ®rst performed the growth inhibition assays, before we collected the cells for RNA isolation and Western blotting. Since after prolonged culture the basal growth rate of clone 9 was strongly reduced compared to the other cell lines and the TGF-b response disappeared, it is possible that in this cell line a constitutively active N-terminally truncated DPC4 protein is induced during culture by a partial deletion of the DPC4 construct. Actually, it has been demonstrated that removal of the N-terminal domain of MAD related proteins, including DPC4, results in a ligand independent activation of the Cterminal domain Liu et al., 1996) .
Activin induces growth inhibition and transcription of PAI-1 via a type I receptor that is closely related to the TGF-b type I receptor (Carcamo et al., 1994) . We were however not able to restore activin responses by transfection of DPC4 alone or in combination with Smad2. This indicates that the MDA-MB-468 cells may lack a component of the activin speci®c part of the signalling pathway, although we cannot exclude that the mutation P303L in the proline rich linker region of the DPC4 construct we used is responsible for the inability to restore activin responses. If so, this mutation is introduced during the PCR reaction used to amplify DPC4 from MDA-MB-231 cells, because activin can induce the 3TPlux construct in MDA-MB-231 cells after transfection of the activin type IB receptor, indicating that in these cells the downstream components of the activin signalling pathway are functional. It is also possible that DPC4 is not involved in the activin signal transduction pathway and that the absence of growth inhibition by TGF-b and activin in MDA-MB-468 cells does result from another common defect. The lack of activin eects after transfection of MDA-MB-468 cells with DPC4 and/or Smad2 contrasts with the results of Lagna et al. (1996) . This might be explained by the use of higher amounts of DNA in their transfections, which might result in higher transfection eciencies and higher expression of the constructs. We also did not ®nd an enhancement of the TGF-b eects by cotransfecting DPC4 and Smad2, probably because of squelching, since the Smad2 construct was transcribed and/or translated more eciently than the DPC4 construct as demonstrated by Western blotting (de Winter, unpublished data). However, in Mv1Lu cells DPC4 and Smad2 did synergize in the induction of the 3TPlux reporter construct (ten Dijke, unpublished data).
In MDA-MB-231 the TGF-b signal transduction pathway leading to the induction of the 3TPlux and PAIluc reporters appeared to be intact, whereas the signalling pathway involved in growth inhibition seems to be mutated (Kalkhoven et al., 1995) . Possibly defects can be found at the level of cell cycle control, which are probably only manifested under speci®c culture conditions or in speci®c subpopulations of MDA-MB-231 cells, since growth inhibition by TGF-b in this cell line has been found by others (Zugmaier, 1989; Jeng et al., 1993; Gucev et al., 1996) .
The presence of an alternatively spliced DPC4 transcript in MDA-MB-231 cells that encodes a DPC4 protein missing amino acid resides 223 to 301 in the proline rich linker region might result from a mutation in the DPC4 gene causing inappropriate splicing. The proline rich linker region of DPC4 is much longer than the linker region in other MAD related proteins, which may be important for its function. This hypothesis is strengthened by our ®nding that the alternatively spliced DPC4 transcript encodes a functional inactive DPC4 protein, although again, we cannot exclude that the additional mutations H92R and Q334R in this DPC4 protein aect its function. The alternatively spliced DPC4 construct is also not acting as a dominant negative DPC4, like has been shown for a C-terminal deletion of 39 amino acid residues in the DPC4 protein (Lagna et al., 1996; Zhang et al., 1996) . This suggests that the proline rich linker region might be important for interaction with other molecules in the TGF-b signalling cascade. In T47D breast tumour cells, which are growth inhibited by activin and by TGF-b after transfection of the TGF-b type II receptor (Kalkhoven et al., 1995) , no induction of the 3TPlux reporter by activin or TGF-b is found and transfection of DPC4 or Smad2 does not restore the 3TPlux response (de Winter, unpublished results). This indicates that in these cells probably a defect in the PAI-1 speci®c part of the signalling cascade can be found. Possibly defects in the mitogenactivated protein kinase kinase kinase TAK1 or its activator TAB1, which have been implicated in the regulation of PAI-1 by TGF-b (Yamaguchi et al., 1995; Shibuya et al., 1996) , are present in these cells. It is also possible that the MAD related proteins interact with dierent transcription factors to form active complexes and that the interaction with one of these transcription factors is disturbed in T47D cells.
In summary, these results demonstrate that DPC4 is involved in TGF-b induced growth inhibition and transcriptional response and propose that DPC4 has the potency of a tumour suppressor gene, as suggested from its deletion in pancreas carcinomas. Our results also show that breast tumour cells are suitable tools for studying defects in signal transduction by TGF-b and activin.
Materials and methods

Materials
Dulbecco's modi®ed Eagle's medium and Ham's F12 medium were obtained from Gibco (Grand Island, NY) and fetal calf serum (FCS) was purchased from Integro (Linz, Australia). Bovine insulin and human transferrin were from Sigma (St Louis, MO). TGF-b1 was puri®ed from human platelets as described (Van den Eijnden-van Raaij et al., 1988) . Recombinant bovine activin-A was obtained from Innogenetics, SA (Ghent, Belgium). Radiochemicals ([methyl- 3 H]thymidine and [a 32 P]dCTP) were from Amersham. The TGF-b and activin responsive 3TP-lux reporter construct, containing three TPA response elements and region 7740 to 7636 of the plasminogen activator inhibitor 1 promoter in front of the luciferase gene (Wrana et al., 1992) , was a gift of Dr J MassagueÂ (New York, USA). A reporter construct containing region 7800 to +75 of the plasminogen activator inhibitor 1 promoter in front of the luciferase gene (PAI-luc) (Keeton et al., 1991) was obtained from Dr DJ Loskuto (La Jolla, USA). The cDNA encoding Smad2 was cloned from a human brain cDNA library (Nakao et al., in press ). The mouse activin type IB receptor cDNA was obtained from Dr K Miyazono (Tokyo, Japan) and cloned in an expression vector containing the human b-actin promoter as described (de Winter et al., 1996) .
Cell culture and proliferation assays
MCF-7 cells were kindly provided by Dr C Quirin-Stricker (Strasbourg, France) and T47D cells were given by Dr RL Sutherland (Sydney, Australia). All other cell lines were obtained from ATCC. Cells were grown in a 1 : 1 mixture of Dulbecco's minimal essential medium and Ham's F12 medium (DF), buered with NaHCO 3 (44 mM) in a humidi®ed atmosphere containing 7.5% CO 2 (DF-bic) and supplemented with 7.5% FCS.
The proliferation assays were performed in DF-bic containing 10% dithiothreitol (DTT) treated FCS (to inactivate polypeptide growth factors), supplemented with 5 mg/ml insulin, 30 nM selenite and 10 mg/ml transferrin (DFthiol). Cells were seeded at a density of 2610 4 cells/well in a 24 well plate containing DF-thiol. After 24 h the medium was refreshed and TGF-b1 or activin-A were added. Another 24 h later medium was refreshed again. For the last 16 h of the 72 h incubation with TGF-b1 or activin-A [methyl-3 H] thymidine (0.5 mCi/well) was added. Subsequently, the cells were washed with Trichloroacetic acid (TCA) and lysed with NaOH, followed by liquid scintillation counting as described (Van der Burg et al., 1989) . [ 3 H]thymidine incorporation in TGF-b1 and activin-A treated cells was compared with untreated cells.
Isolation of stable transfectants
MDA-MB-468 cells were grown in six well plates in DF-bic supplemented with 7.5% FCS. Cells were transfected overnight by a standard calcium phosphate precipitation method with a pcDNA3 construct encoding DPC4 cDNA under control of the CMV promoter and the neomycine resistance gene under control of the SV40 promoter. After transfection, the medium was refreshed and 600 mg geneticin (G418)/ml culture medium was added. Resistant colonies were isolated and cultured under continuous G418 selection.
Luciferase assay
Cells were cultured in six well plates in DF-bic with 7.5% FCS and transiently transfected with the 3TP-lux reporter construct or the PAI-luc reporter construct in combination with a lac-Z reporter construct by a standard calcium phosphate precipitation method. After transfection, cells were cultured for 18 h in the presence or absence of TGFb1 or activin-A. Cells were then lysed in 500 ml lysis buer (1% Triton, 25 mM glycylglycin, 15 mM MgSO 4 , 4 mM EGTA and 1 mM DTT). Luciferase activity was measured in a Lumac 3M biocounter, by addition of 265 ml assay buer (3.8 mM ATP, 34 mM glycylglycin and 20 mM MgSO 4 ) and 100 ml 0.2 mM luciferine (Boehringer Mannheim) to 75 ml lysate. Lac-Z activity was determined by measuring the conversion of o-nitro-phenyl b-D-galactopyranoside (Sigma) in a BioRad microplate reader at 420 nm. Luciferase activity was corrected for lac-Z activity. Induction of luciferase activity by TGF-b or activin was calculated by comparing luciferase activity in cells cultured in the presence or absence of TGF-b or activin.
RNA isolation, reverse transcription PCR and Northern blot analysis
Total RNA was isolated by the acid-phenol extraction method (Chomczynski and Sacchi, 1987) from cells cultured in petri dishes (diameter 8.5 cm, Nunc). Reverse transcription PCR was performed exactly as described (Roelen et al., 1994) . For cloning the human DPC4 transcripts 5'-TTTCCTTGCAACGTTAGCTG-3' as forward primer and 5'-CAGTCTAAAGGTTGTGGGTC-3' as reverse primer were used to amplify a region corresponding to bp 28 ± 1786 of the human sequence from oligo (dT) primed cDNA. The ampli®ed products were cloned into pGEM-T (Promega, Madison, WI) subcloned into pcDNA3 (InVitrogen, San Diego, CA) and sequenced using an automatic sequencer (Applied Biosystems).
For RT ± PCR ampli®cation of DPC4 mRNA from stably transfected MDA-MB-468 breast tumour cells cDNA was made using the reverse primer described above. PCR was performed with the forward primer described above or with 5'-GTCTCTGGAGGTGGCCTGAT-3' as forward primer and 5'-ACCGCGTGGTCACTAAGGCA-3' as reverse primer to amplify regions corresponding to bp 28 ± 1348 or bp 418 ± 1348 of the human DPC4 sequence respectively. All PCR reactions were carried out at an annealing temperature of 558C. PCR products were loaded on 1% agarose gels and visualised with ethidium bromide.
Northern blot analysis was performed as described (Van den Eijnden-van Raaij et al., 1992) using 32 P-labelled cDNA probes corresponding to the entire coding sequence of DPC4, Smad2 and GAPDH as a control.
Isolation of genomic DNA and Southern blot analysis
Genomic DNA was isolated by incubating cells overnight at 378C in digestion buer (100 mM NaCl, 10 mM Tris (pH 8.0), 25 mM EDTA, 0.5% SDS and 20 mg/ml proteinase K). Subsequently, RNase-A was added to a ®nal concentration of 0.5 mg/ml and the incubation was continued for another hour. The lysate was phenol/ chloroform extracted and the DNA was ethanol precipitated. The genomic DNA (30 mg) was digested with HindIII for 16 h and fragments were separated on a 0.5% agarose gel. The DNA was blotted onto a nitrocellulose ®lter and hybridised with 32 P-labelled cDNA probes corresponding to the entire coding sequence of DPC4 or Smad2.
Preparation of polyclonal DPC4 antibody
A synthetic peptide corresponding to amino acid residues 184 ± 203 (HPPSNRASTETYSTPALLA) in a nonconserved region of the proline rich linker region of the DPC4 protein was coupled to keyhole limpet hemocyanin (Calbiochem-Behring) using glutaaraldehyde, mixed with Freund's and used to immunise rabbits. The antiserum recognizes a GST-DPC4 fusion protein on Western blot, precipitates DPC4 in immunoprecipitation experiments and does not crossreact with Smad1, Smad2, Smad3 or Smad5 (Nakao, unpublished results) .
Western blotting
Stably transfected MDA-MB-468 cells were cultured in six well plates. Cells were scrapped from the wells in phosphate buered saline, centrifuged for 5 min and the cell pellet was resolved in sample buer (100 mM Tris (pH 6.8), 10% glycerol, 1% SDS, 10 mM DTT). Proteins were separated by SDS ± PAGE and electrotransferred to Immobilon-P (Millipore). DPC4 protein was detected using a polyclonal antibody against amino acid resides 184 ± 203 in the proline rich linker region of the DPC4 protein, which was visualised with streptavidin-horseradish peroxidase conjugate (Amersham) using the enhanced chemoluminescence system (ECL, Amersham).
